Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Up 7.1% in November

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.1% from the October 31st total of 3,500,000 shares. Currently, 14.5% of the company’s stock are short sold. Based on an average trading volume of 336,300 shares, the short-interest ratio is presently 11.2 days.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 3,630 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at about $71,000. The Manufacturers Life Insurance Company purchased a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at about $82,000. Signature Estate & Investment Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 2nd quarter valued at about $88,000. Finally, MetLife Investment Management LLC increased its stake in shares of Inovio Pharmaceuticals by 129.1% during the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 8,546 shares during the period. Institutional investors own 26.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on INO shares. Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday, November 18th. Royal Bank of Canada cut their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Friday, November 15th. Finally, HC Wainwright lowered their price objective on Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating on the stock in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $38.00.

Inovio Pharmaceuticals Price Performance

Shares of INO stock opened at $4.35 on Tuesday. Inovio Pharmaceuticals has a 12-month low of $3.85 and a 12-month high of $14.75. The stock has a 50 day simple moving average of $5.21 and a 200-day simple moving average of $7.56.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.